$HOTH
Hoth Therapeutics, Inc. Stock $hoth

$hoth Overview Financials Valuation SEC Filings Company Website

2023 Q2 Form 10-Q Financial Statement

#000121390023039789 Filed on May 15, 2023

Income Statement

Concept	2023 Q2	2023 Q1	2022 Q1
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$1.010M	$927.1K	$1.458M
YoY Change	325.13%	-36.43%	-40.72%
% of Gross Profit
Research & Development	$641.0K	$890.8K	$989.7K
YoY Change	-34.0%	-9.98%	-39.29%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses	$1.709M	$2.193M	$2.661M
YoY Change	-25.7%	-17.58%	-37.69%
Operating Profit	-$1.709M	-$2.193M	-$2.661M
YoY Change	-25.7%	-17.58%
Interest Expense	-$164.4K	$9.310K	$47.50K
YoY Change	-56.48%	-80.4%
% of Operating Profit
Other Income/Expense, Net	-$164.4K	$9.310K	$41.69K
YoY Change	-56.51%	-77.67%	316.9%
Pretax Income	-$1.873M	-$2.184M	-$2.572M
YoY Change	-30.05%	-15.09%	-39.64%
Income Tax
% Of Pretax Income
Net Earnings	-$1.873M	-$2.184M	-$2.572M
YoY Change	-30.05%	-15.09%	-39.64%
Net Earnings / Revenue
Basic Earnings Per Share	-$0.57	-$0.88	-$2.68
Diluted Earnings Per Share	-$0.57	-$0.88	-$107.3K
COMMON SHARES
Basic Shares Outstanding	3.302M shares	3.302M shares	959.0K shares
Diluted Shares Outstanding	3.302M shares	2.483M shares	959.0K shares

Balance Sheet

Concept	2023 Q2	2023 Q1	2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$11.57M	$13.23M	$8.296M
YoY Change	-0.45%	59.54%	-59.24%
Cash & Equivalents	$11.54M	$13.04M	$6.381M
Short-Term Investments	$24.57K	$190.5K	$1.915M
Other Short-Term Assets	$314.9K	$193.7K	$189.7K
YoY Change	64.7%	2.11%	5.38%
Inventory
Prepaid Expenses	$314.9K	$193.7K
Receivables
Other Receivables
Total Short-Term Assets	$11.88M	$13.43M	$8.535M
YoY Change	0.18%	57.33%	-58.43%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$33.00K	$33.00K	$410.0K
YoY Change	-91.48%	-91.95%	0.0%
Other Assets
YoY Change
Total Long-Term Assets	$33.00K	$33.00K	$410.0K
YoY Change	-91.48%	-91.95%	-10.87%
TOTAL ASSETS
Total Short-Term Assets	$11.88M	$13.43M	$8.535M
Total Long-Term Assets	$33.00K	$33.00K	$410.0K
Total Assets	$11.92M	$13.46M	$8.945M
YoY Change	-2.72%	50.49%	-57.38%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$520.7K	$782.8K	$699.8K
YoY Change	-23.37%	11.86%	20.66%
Accrued Expenses	$1.162M	$530.1K	$126.0K
YoY Change	2258.26%	320.88%	-30.03%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$1.716M	$1.346M	$825.8K
YoY Change	127.7%	63.01%	8.65%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$250.0K	$250.0K	$235.0K
YoY Change	-9.09%	6.38%	-18.97%
Total Long-Term Liabilities	$250.0K	$250.0K	$235.0K
YoY Change	-9.09%	6.38%	-18.97%
TOTAL LIABILITIES
Total Short-Term Liabilities	$1.716M	$1.346M	$825.8K
Total Long-Term Liabilities	$250.0K	$250.0K	$235.0K
Total Liabilities	$1.966M	$1.596M	$1.061M
YoY Change	91.13%	50.46%	2.0%
SHAREHOLDERS EQUITY
Retained Earnings	-$49.16M	-$47.28M
YoY Change	26.12%
Common Stock	$330.00	$330.00
YoY Change	-89.75%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$9.951M	$11.87M	$7.884M
YoY Change
Total Liabilities & Shareholders Equity	$11.92M	$13.46M	$8.945M
YoY Change	-2.72%	50.49%	-57.38%

Cashflow Statement

Concept	2023 Q2	2023 Q1	2022 Q1
OPERATING ACTIVITIES
Net Income	-$1.873M	-$2.184M	-$2.572M
YoY Change	-30.05%	-15.09%	-39.64%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities	-$1.450M	-$2.289M	-$2.136M
YoY Change	-34.78%	7.16%	-21.45%
INVESTING ACTIVITIES
Capital Expenditures	$0.00	$0.00	-$25.00K
YoY Change	-100.0%	-100.0%	-64.29%
Acquisitions
YoY Change
Other Investing Activities	$0.00		$0.00
YoY Change	-100.0%		-100.0%
Cash From Investing Activities	$0.00		-$25.00K
YoY Change	-100.0%		-102.6%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$0.00
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	0.000	$8.911M
YoY Change	-100.0%
NET CHANGE
Cash From Operating Activities	-1.450M	-$2.289M	-2.136M
Cash From Investing Activities	0.000		-25.00K
Cash From Financing Activities	0.000	$8.911M
Net Change In Cash	-1.450M	$6.622M	$0.00
YoY Change	-129.31%		-100.0%
FREE CASH FLOW
Cash From Operating Activities	-$1.450M	-$2.289M	-$2.136M
Capital Expenditures	$0.00	$0.00	-$25.00K
Free Cash Flow	-$1.450M	-$2.289M	-$2.111M
YoY Change	-33.23%	8.43%	-20.32%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.68
CY2023Q1	dei	Document Type DocumentType	10-Q
CY2023Q1	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2023Q1	dei	Document Period End Date DocumentPeriodEndDate	2023-03-31
CY2023Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023Q1	dei	Document Transition Report DocumentTransitionReport	false
CY2023Q1	dei	Entity File Number EntityFileNumber	001-38803
CY2023Q1	dei	Entity Registrant Name EntityRegistrantName	Hoth Therapeutics, Inc.
CY2023Q1	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	NV
CY2023Q1	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	82-1553794
CY2023Q1	dei	Entity Address Address Line1 EntityAddressAddressLine1	1 Rockefeller Plaza
CY2023Q1	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 1039
CY2023Q1	dei	Entity Address City Or Town EntityAddressCityOrTown	New York
CY2023Q1	dei	Entity Address State Or Province EntityAddressStateOrProvince	NY
CY2023Q1	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	10020
CY2023Q1	dei	City Area Code CityAreaCode	(646)
CY2023Q1	dei	Local Phone Number LocalPhoneNumber	756-2997
CY2023Q1	dei	Security12b Title Security12bTitle	Common Stock, $0.0001 par value
CY2023Q1	dei	Trading Symbol TradingSymbol	HOTH
CY2023Q1	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2023Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023Q1	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023Q1	dei	Entity Small Business EntitySmallBusiness	true
CY2023Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2023Q1	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
CY2023Q1	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	3302113	shares
CY2023Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	13044382	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	6428611	usd
CY2023Q1	us-gaap	Marketable Securities MarketableSecurities	190517	usd
CY2022Q4	us-gaap	Marketable Securities MarketableSecurities	209320	usd
CY2023Q1	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	193693	usd
CY2022Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	88450	usd
CY2023Q1	us-gaap	Assets Current AssetsCurrent	13428592	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	6726381	usd
CY2023Q1	us-gaap	Investments In Affiliates Subsidiaries Associates And Joint Ventures InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures	33000	usd
CY2022Q4	us-gaap	Investments In Affiliates Subsidiaries Associates And Joint Ventures InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures	33000	usd
CY2023Q1	us-gaap	Assets Assets	13461592	usd
CY2022Q4	us-gaap	Assets Assets	6759381	usd
CY2023Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	782831	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	694989	usd
CY2023Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	530103	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	667742	usd
CY2023Q1	hoth	Accrued License Fee Current Portion AccruedLicenseFeeCurrentPortion	33125	usd
CY2022Q4	hoth	Accrued License Fee Current Portion AccruedLicenseFeeCurrentPortion	25000	usd
CY2023Q1	us-gaap	Liabilities Current LiabilitiesCurrent	1346059	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	1387731	usd
CY2023Q1	hoth	Accrued License Fee Non Current Portion AccruedLicenseFeeNonCurrentPortion	250000	usd
CY2022Q4	hoth	Accrued License Fee Non Current Portion AccruedLicenseFeeNonCurrentPortion	250000	usd
CY2023Q1	us-gaap	Liabilities Liabilities	1596059	usd
CY2022Q4	us-gaap	Liabilities Liabilities	1637731	usd
CY2023Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2023Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2023Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2023Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	50000000	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	50000000	shares
CY2023Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	3302113	shares
CY2023Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	3302113	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	1302113	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	1302113	shares
CY2023Q1	us-gaap	Common Stock Value CommonStockValue	330	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	130	usd
CY2023Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	59120450	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	50198630	usd
CY2023Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-47282623	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-45099116	usd
CY2023Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	27376	usd
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	22006	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	11865533	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	5121650	usd
CY2023Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	13461592	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	6759381	usd
CY2023Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	890845	usd
CY2022Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	948379	usd
CY2023Q1	hoth	Research And Development License Acquired ResearchAndDevelopmentLicenseAcquired	48033	usd
CY2022Q1	hoth	Research And Development License Acquired ResearchAndDevelopmentLicenseAcquired	41272	usd
CY2023Q1	hoth	Compensation And Related Expensesincluding Stockbased Compensation CompensationAndRelatedExpensesincludingStockbasedCompensation	295564	usd
CY2022Q1	hoth	Compensation And Related Expensesincluding Stockbased Compensation CompensationAndRelatedExpensesincludingStockbasedCompensation	957769	usd
CY2023Q1	us-gaap	Professional Fees ProfessionalFees	616375	usd
CY2022Q1	us-gaap	Professional Fees ProfessionalFees	486701	usd
CY2023Q1	hoth	Rent Expenses RentExpenses	15120	usd
CY2022Q1	hoth	Rent Expenses RentExpenses	13896	usd
CY2023Q1	us-gaap	Other Selling General And Administrative Expense OtherSellingGeneralAndAdministrativeExpense	326880	usd
CY2022Q1	us-gaap	Other Selling General And Administrative Expense OtherSellingGeneralAndAdministrativeExpense	212677	usd
CY2023Q1	us-gaap	Operating Expenses OperatingExpenses	2192817	usd
CY2022Q1	us-gaap	Operating Expenses OperatingExpenses	2660694	usd
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-2192817	usd
CY2022Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-2660694	usd
CY2023Q1	us-gaap	Marketable Securities Gain Loss MarketableSecuritiesGainLoss	-18803	usd
CY2022Q1	us-gaap	Marketable Securities Gain Loss MarketableSecuritiesGainLoss	21949	usd
CY2023Q1	us-gaap	Interest Income Other InterestIncomeOther	28113	usd
CY2022Q1	us-gaap	Interest Income Other InterestIncomeOther	25553	usd
CY2022Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	41685	usd
CY2023Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	9310	usd
CY2022Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	89187	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-2183507	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-2571507	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-5370	usd
CY2022Q1	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	3730	usd
CY2023Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-2188877	usd
CY2022Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-2567777	usd
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.88
CY2022Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.68
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	2482824	shares
CY2022Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	959021	shares
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	5121650	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	1860	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	10630	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	8909530	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-5370	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-2183507	usd
CY2023Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	11865533	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	9882292	usd
CY2022Q1	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	577438	usd
CY2022Q1	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	3730	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-2571507	usd
CY2022Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	7884493	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-2183507	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-2571507	usd
CY2023Q1	hoth	Research And Developmentlicenses Acquired Expensed ResearchAndDevelopmentlicensesAcquiredExpensed	8125	usd
CY2022Q1	hoth	Research And Developmentlicenses Acquired Expensed ResearchAndDevelopmentlicensesAcquiredExpensed	25000	usd
CY2023Q1	us-gaap	Share Based Compensation ShareBasedCompensation	10630	usd
CY2022Q1	us-gaap	Share Based Compensation ShareBasedCompensation	577438	usd
CY2023Q1	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	-18803	usd
CY2022Q1	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	21949	usd
CY2023Q1	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	96244	usd
CY2022Q1	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	92556	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-47225	usd
CY2022Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-52915	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-2289419	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-2136489	usd
CY2022Q1	us-gaap	Payments To Acquire In Process Research And Development PaymentsToAcquireInProcessResearchAndDevelopment	25000	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-25000	usd
CY2023Q1	hoth	Proceed From Issuance Common Stock Common Stock Warrants And Prefunded Warrants Net Of O ProceedFromIssuanceCommonStockCommonStockWarrantsAndPrefundedWarrantsNetOfO	8909530	usd
CY2023Q1	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	1860	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	8911390	usd
CY2023Q1	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-6201	usd
CY2022Q1	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	4001	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	6621971	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-2161489	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	6428611	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	8538270	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	13044382	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	6380782	usd
CY2022Q4	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	140000	shares
CY2022Q4	hoth	Common Stock Shares Purchase CommonStockSharesPurchase	1860000	shares
CY2022Q4	hoth	Warrants Purchase To Shares WarrantsPurchaseToShares	2500000	shares
CY2022Q4	hoth	Common Stock At Purchase Price CommonStockAtPurchasePrice	5
CY2022Q4	hoth	Aggregate Gross Proceeds AggregateGrossProceeds	10000000	usd
CY2022Q4	us-gaap	Stock Option Exercise Price Increase StockOptionExercisePriceIncrease	5
CY2023Q1	hoth	Warrant Exercisable Term Description WarrantExercisableTermDescription	The December Wainwright Warrants are exercisable for a period of five and one-half years from the issuance date at an exercise price of $6.25 per share, subject to adjustment, and may, under certain circumstances, be exercised on a cashless basis.
CY2023Q1	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Reclassifications</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Certain reclassifications have been made to prior year financial statements to conform to classifications used in the current year. These reclassifications had no impact on net income (loss), stockholder’s equity or cash flows as previously reported.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i> </i></b></p>
CY2023Q1	us-gaap	Use Of Estimates UseOfEstimates	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Use of estimates</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of expenses during the reporting periods. The most significant estimates in the Company’s condensed consolidated financial statements relate to stock-based compensation and the valuation allowance of deferred tax assets resulting from net operating losses. These estimates and assumptions are based on current facts, historical experience and various other factors believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of expenses that are not readily apparent from other sources. Actual results may differ materially and adversely from these estimates. To the extent there are material differences between the estimates and actual results, the Company’s future results of operations may be affected.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p>
CY2023Q1	us-gaap	Proceeds From Bank Debt ProceedsFromBankDebt	13044382	usd
CY2022	us-gaap	Proceeds From Bank Debt ProceedsFromBankDebt	6428611	usd
CY2023Q1	us-gaap	Federal Deposit Insurance Corporation Premium Expense FederalDepositInsuranceCorporationPremiumExpense	250000	usd
CY2023Q1	us-gaap	Cash Uninsured Amount CashUninsuredAmount	12221474	usd
CY2022Q4	us-gaap	Cash Uninsured Amount CashUninsuredAmount	5542838	usd
CY2023Q1	hoth	Australian Bank Accounts AustralianBankAccounts	322908	usd
CY2022	hoth	Australian Bank Accounts AustralianBankAccounts	385771	usd
CY2023Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	3110875	shares
CY2022Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	507567	shares
CY2023Q1	hoth	Schedule Of Research And Development Expenses For Licenses Acquired ScheduleOfResearchAndDevelopmentExpensesForLicensesAcquired	<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Three Months Ended<br/> March 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left">The George Washington University</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">41,158</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">16,272</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">North Carolina State University</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-36">—</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">20,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Virginia Commonwealth University</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">6,250</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-37">—</div></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td>University of Cincinnati</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">625</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">5,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td style="font-weight: bold; padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">48,033</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">41,272</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"> </td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p>
CY2023Q1	hoth	Research And Development Expenses ResearchAndDevelopmentExpenses	48033	usd
CY2022	hoth	Research And Development Expenses ResearchAndDevelopmentExpenses	41272	usd
CY2023Q1	us-gaap	Costs And Expenses CostsAndExpenses	30000	usd
CY2023Q1	us-gaap	Marketable Securities MarketableSecurities	190517	usd
CY2023Q1	us-gaap	Investments In Affiliates Subsidiaries Associates And Joint Ventures InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures	33000	usd
CY2022Q4	us-gaap	Marketable Securities MarketableSecurities	209320	usd
CY2022Q4	us-gaap	Investments In Affiliates Subsidiaries Associates And Joint Ventures InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures	33000	usd
CY2022Q4	us-gaap	Investments Fair Value Disclosure InvestmentsFairValueDisclosure	33000	usd
CY2023Q1	us-gaap	Investments Fair Value Disclosure InvestmentsFairValueDisclosure	33000	usd
CY2021Q4	us-gaap	Investments Fair Value Disclosure InvestmentsFairValueDisclosure	410000	usd
CY2022Q1	us-gaap	Investments Fair Value Disclosure InvestmentsFairValueDisclosure	410000	usd
CY2020Q1	hoth	Purchased Percentage PurchasedPercentage	5	usd
CY2020Q1	hoth	Outstanding Membership Interests OutstandingMembershipInterests	250000	usd
CY2020Q1	hoth	Membership Interests MembershipInterests	0.25	pure
CY2020Q1	us-gaap	Payments To Minority Shareholders PaymentsToMinorityShareholders	3000000	usd
CY2020Q1	us-gaap	Purchase Options Land PurchaseOptionsLand	250000	usd
CY2020Q1	hoth	Interest Purchase Agreement InterestPurchaseAgreement	0.01	pure
CY2020Q1	us-gaap	Supplemental Deferred Purchase Price SupplementalDeferredPurchasePrice	100000	usd
CY2022	us-gaap	Asset Impairment Charges AssetImpairmentCharges	400000	usd
CY2023Q1	us-gaap	Investment Income Investment Expense InvestmentIncomeInvestmentExpense	0	usd
CY2022	us-gaap	Investment Income Investment Expense InvestmentIncomeInvestmentExpense	0	usd
CY2022	us-gaap	Change In Unrealized Gain Loss On Hedged Item In Fair Value Hedge1 ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1	27000	usd
CY2023Q1	us-gaap	Investment Owned At Fair Value InvestmentOwnedAtFairValue	33000	usd
CY2022Q4	us-gaap	Investment Owned At Fair Value InvestmentOwnedAtFairValue	33000	usd
CY2023Q1	us-gaap	Securities Purchased Under Agreements To Resell Setoff Rights Description SecuritiesPurchasedUnderAgreementsToResellSetoffRightsDescription	On December 29, 2022, the Company entered into a securities purchase agreement with an accredited investor pursuant to which it sold (i) 140,000 shares of common stock, (ii) December Pre-Funded Warrants to purchase up to 1,860,000 shares of common stock and (iii) December Common Stock Warrants to purchase up to 2,500,000 shares of common stock at a purchase price of $5.00 per share and accompanying warrant (less $0.001 for each December Pre-Funded Warrant) in a private placement for aggregate gross proceeds of approximately $10 million, exclusive of placement agent commission and fees and other offering expenses, and approximately $8.9 million in net proceeds. The closing of the offering occurred on January 3, 2023.
CY2021Q1	us-gaap	Stock Issued During Period Shares Issued For Services StockIssuedDuringPeriodSharesIssuedForServices	66878	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	3384	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	3.16
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	3384	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	3.16
CY2023Q1	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	8000	usd
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Outstanding Weighted Average Remaining Contractual Terms ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms	P1Y2M12D
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	104651	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	49.8
CY2023Q1	hoth	Rfl Sharebased Compensation Arrangement By Sharebased Payment Award Option Outstanding Weighted Average Remaining Contractual Term2 rfl_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionOutstandingWeightedAverageRemainingContractualTerm2	P8Y3M18D
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	104651	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	49.8
CY2023Q1	hoth	Weighted Average Remaining Contractual Lifein Years Outstanding Ending Balance WeightedAverageRemainingContractualLifeinYearsOutstandingEndingBalance	P8Y1M6D
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber	104651	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice	49.8
CY2023Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P8Y1M6D
CY2023Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Nonvested SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested	0	usd
CY2023Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	10630	usd
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	577438	usd
CY2022Q4	us-gaap	Common Unit Issued CommonUnitIssued	140000	shares
CY2022Q4	us-gaap	Stock Issued During Period Shares Purchase Of Assets StockIssuedDuringPeriodSharesPurchaseOfAssets	2500000	shares
CY2022Q4	hoth	Purchase Price Per Share PurchasePricePerShare	5
CY2022Q4	hoth	Accompanying Warrant Per Share AccompanyingWarrantPerShare	0.001
CY2022Q4	hoth	Gross Proceeds GrossProceeds	10000000	usd
CY2022Q4	hoth	Common Stock Warrant Term Description CommonStockWarrantTermDescription	Each December Common Stock Warrant is exercisable for a period of five and one-half years from the issuance date at an exercise price of $5.00 per share, subject to adjustment, and may, under certain circumstances, be exercised on a cashless basis.
CY2022Q4	us-gaap	Warrant Exercise Price Decrease WarrantExercisePriceDecrease	5
CY2023Q1	hoth	Issuance Term IssuanceTerm	P6Y6M21D
CY2023Q1	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	0.001
CY2023Q1	us-gaap	Long Term Debt Term LongTermDebtTerm	P30Y
CY2023Q1	us-gaap	Warrant Exercise Price Decrease WarrantExercisePriceDecrease	5
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	1.3507	pure
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0394	pure
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2023Q1	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	15	usd
CY2023Q1	us-gaap	Shortterm Debt Fair Value ShorttermDebtFairValue	591090	usd
CY2023Q1	hoth	Schedule Of Warrant Activity ScheduleOfWarrantActivity	<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="white-space: nowrap"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number of<br/> Warrants</td><td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted<br/> Average<br/> Exercise<br/> Price</td><td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Total<br/> Intrinsic<br/> Value</td><td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted<br/> Average<br/> Remaining<br/> Contractual Life <br/> (in years)</td><td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%; padding-bottom: 1.5pt">Outstanding as of December 31, 2022</td><td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">402,840</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">49.73</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-60">—</div></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">1.4</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td>Issued</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4,460,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2.94</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-61">—</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-62">—</div></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Expired</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-63">—</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-64"> —</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-65">—</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-66">—</div></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-bottom: 1.5pt">Exercised</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,860,000</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">0.001</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-67">—</div></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-68">—</div></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt">Outstanding as of March 31, 2023</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,002,840</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">11.04</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-69">—</div></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">4.83</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-bottom: 4pt">Warrants exercisable as of March 31, 2023</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">3,002,840</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">11.04</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-70">—</div></td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">4.83</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p>
CY2023Q1	hoth	Leases Office Spaces LeasesOfficeSpaces	4500	usd
CY2023Q1	us-gaap	Payments For Rent PaymentsForRent	15120	usd
CY2022	us-gaap	Payments For Rent PaymentsForRent	13896	usd
CY2023Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense		usd
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.88
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	2482824	shares
CY2022Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	959021	shares
CY2023Q1	us-gaap	Payments To Acquire In Process Research And Development PaymentsToAcquireInProcessResearchAndDevelopment		usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities		usd
CY2022Q1	hoth	Proceed From Issuance Common Stock Common Stock Warrants And Prefunded Warrants Net Of O ProceedFromIssuanceCommonStockCommonStockWarrantsAndPrefundedWarrantsNetOfO		usd
CY2022Q1	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises		usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities		usd
CY2023Q1	us-gaap	Fair Value Option Changes In Fair Value Gain Loss1 FairValueOptionChangesInFairValueGainLoss1		usd
CY2022Q1	us-gaap	Fair Value Option Changes In Fair Value Gain Loss1 FairValueOptionChangesInFairValueGainLoss1		usd
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross		shares
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod		shares
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
CY2022Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Outstanding SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding		usd
CY2023Q1	us-gaap	Stock Issued During Period Shares Employee Stock Ownership Plan StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan		shares
CY2023Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
CY2023Q1	hoth	Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Issued SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueIssued		usd
CY2023Q1	hoth	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Issued SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualIssued
CY2023Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Outstanding SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding		usd
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue		usd
CY2023Q1	dei	Amendment Flag AmendmentFlag	false
CY2023Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2023Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001711786

Files In Submission

Name	View Source	Status
f10q0323_hoththerap_htm.xml	Edgar Link	completed
0001213900-23-039789-index-headers.html	Edgar Link	pending
0001213900-23-039789-index.html	Edgar Link	pending
0001213900-23-039789.txt	Edgar Link	pending
0001213900-23-039789-xbrl.zip	Edgar Link	pending
f10q0323ex31-1_hoththerap.htm	Edgar Link	pending
f10q0323ex31-2_hoththerap.htm	Edgar Link	pending
f10q0323ex32-1_hoththerap.htm	Edgar Link	pending
f10q0323ex32-2_hoththerap.htm	Edgar Link	pending
f10q0323_hoththerap.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
hoth-20230331.xsd	Edgar Link	pending
hoth-20230331_cal.xml	Edgar Link	unprocessable
hoth-20230331_def.xml	Edgar Link	unprocessable
hoth-20230331_lab.xml	Edgar Link	unprocessable
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
hoth-20230331_pre.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$HOTH
Hoth Therapeutics, Inc. Stock $hoth

2023 Q2 Form 10-Q Financial Statement

#000121390023039789 Filed on May 15, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$HOTH Hoth Therapeutics, Inc. Stock $hoth

2023 Q2 Form 10-Q Financial Statement

#000121390023039789 Filed on May 15, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$HOTH
Hoth Therapeutics, Inc. Stock $hoth